About KBI Biopharma
KBI Biopharma is a Healthcare company based in Durham (United States) founded in 1996, and was acquired by JSR Life Sciences in February 2015. Provider of protein formulation, process cell line development, and cGMP services. KBI Biopharma has raised $17 million across 5 funding rounds from investors including NCBiotech, Ballast Point Ventures and INCJ. The company has 1,243 employees. KBI Biopharma has completed 1 acquisition, including Alliance Protein Laboratories. Its website kbibiopharma.com draws about 32 thousand monthly visits. KBI Biopharma offers products and services including Cell Line Development, Process Development, Analytical Development, Formulation Development, and Clinical Manufacturing. Its focus areas include Biopharma Outsourcing, CDMO and Biologics. Its competitors include Aldevron and Omnia Biologics; 1 of its 2 listed competitors has raised funding.
Company details
KBI Biopharma was established in 1996 in Durham, United States, within the biopharmaceutical industry. Core operations encompass protein formulation, process and cell line development, alongside cGMP manufacturing services. These activities support biopharmaceutical clients from preclinical stages through to commercial-scale production. The company maintains its primary location in Durham, facilitating services across various global markets.
- Headquarters Durham, United States
- Employees 1,243
- Stage Acquired
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website kbibiopharma.com
- Social LinkedIn X Facebook
- Acquired by JSR Life Sciences (Feb 2015)
- Annual Revenue$31.68 K (USD)6as on Dec 31, 2023
- Net Profit-$7.46 K (USD)-203as on Dec 31, 2023
- Total Equity Funding$17M (USD)
in 5 rounds
- Latest Funding Round$9.6M (USD), Series A
Aug 2009
- InvestorsNCBiotech
& 4 more
- Employee Count1,243
- Investments & Acquisitions
- Acquired byJSR Life Sciences
(Feb 2015)
Products & Services of KBI Biopharma
KBI Biopharma offers a comprehensive portfolio of products and services, including Cell Line Development, Process Development, Analytical Development, Formulation Development, and Clinical Manufacturing.
Development of cell lines for biopharmaceutical production processes
Creation of scalable processes for new biologic therapeutics
Comprehensive analysis and characterization of biologic molecules
Optimization of formulations for biologic stability and efficacy
GMP manufacturing for clinical-stage biopharmaceuticals
Funding Insights of KBI Biopharma
KBI Biopharma has successfully raised a total of $17M across 5 strategic funding rounds. The most recent funding activity was a Series A round of $9.6 million completed in August 2009. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $17M
- Total Rounds 5
- Last Round Series A — $9.6M
- First Round $1M
(Apr 2003)
- Investors Count 2
All 5 funding rounds of KBI Biopharma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug 2009 | $9.6M | Series A | – | – | – |
| Feb 2009 | $7.4M | Series A | – | – | |
| Sep 2008 | $1.29M | Unspecified | – | – | – |
| Jan 2005 | $2.69M | Debt – Convertible | – | – | – |
| Apr 2003 | $1M | Debt – Venture | – | – |
5 investors in total: 5 institutional.
Investors in KBI Biopharma
KBI Biopharma has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include NCBiotech, Ballast Point Ventures and INCJ.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Expansion capital is provided by Ballast Point Ventures to growing companies. | ballastpointventures.com | Tampa, United States | ||
Biotech startups are incubated and funded in North Carolina. | 1984 | ncbiotech.org | Durham, United States | |
Investment activities in various industries are conducted by INCJ. | incj.co.jp | |||
Creates innovative technologies for raw materials in biopharmaceutical production. | 2012 | jsrlifesciences.com | Sunnyvale, United States | |
Offers ERP software for construction financials, project management, and analytics. | 1974 | cmicglobal.com | Toronto, Canada |
Investor details for KBI Biopharma
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of KBI Biopharma
225 people are tracked at KBI Biopharma (87 in leadership, 138 in team); the tracked headcount is 1,243.
| Name | Role | Group |
|---|---|---|
Fraser Thompson | Director Project Management | Leadership |
Amy Burkhead | Director | Leadership |
Eloe Mondesir | Director Of Quality Control | Leadership |
Kirsten Dysinger | Associate Director | Leadership |
Tom Smith | Director, Quality Control | Leadership |
Andrew Broom | Associate Director, Manufacturing | Leadership |
Sigma Mostafa | Chief Scientific Officer | Leadership |
Chad Cleveland | Global Sr. Director - Computer System Quality | IT Quality | Data Integrity | Leadership |
Matthew Damick | Director Quality Engineering | Leadership |
Kristine Werner Young | Associate Director, Validation | Leadership |
Ashok Bhalla | Associate Director ( Support) | Leadership |
Shaguna Seth | Chief of Staff & Global PMO Head | Leadership |
Olga Buczek | Senior Director Compliance, Mammalian AFS Network | Leadership |
Sarah Holtschlag | Senior Director | Leadership |
Robin Elleston | Director Of Quality Assurance | Leadership |
Logan Behlke | Director, Manufacturing Tech Ops And Compliance | Leadership |
Marc Weber | Senior Director Manufacturing Operations | Leadership |
Fred Goerke | Associate Director Ms&t | Leadership |
Becky McCuen | Director QA | Leadership |
Kevin Tolley | Director | Leadership |
205 more people are available in the full profile.
Complete people profiles for KBI Biopharma
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by KBI Biopharma
KBI Biopharma has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Alliance Protein Laboratories.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Biophysical characterization services for proteins and macromolecules are provided. | ap-lab.com | San Diego, United States | 1998 | Jun 2017 | •••• |
Complete acquisition details for KBI Biopharma
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of KBI Biopharma
5 dated milestones of KBI Biopharma across 21 years, from founding to its latest funding, stage changes and deals.
- Founded KBI Biopharma is founded.
- Funding First funding round of $1.0M.
- Funding Latest funding round, Series A, of $9.6M.
- Exit Acquired by JSR Life Sciences.
- Acquisition Acquires Alliance Protein Laboratories.
Competitors of KBI Biopharma
KBI Biopharma has 2 listed competitors in our database, 1 of them funded. They include Aldevron and Omnia Biologics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| aldevron.com | 1998 | Fargo, United States | 747 | Developer and custom manufacturer of nucleic acids, proteins and antibodies for research, clinical and commercial applications | ||
| omniabio.com | 2001 | Rockville, United States | $25.4M | Process development and manufacturing services for biologics are provided. |
Detailed competitors of KBI Biopharma
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of KBI Biopharma
The website of KBI Biopharma (kbibiopharma.com) receives about 32.5K visits a month and ranks #640,532 among all websites worldwide, #696 in Biotechnology and Pharmaceuticals.
- Monthly visits32.5K
▼ 18.9% vs previous month
- Unique visitors9K
per month
- Global rank#640,532
among all websites
- Category rank#696
Health · Biotechnology and Pharmaceuticals
- Bounce rate38%
- Pages per visit5.1
- Average visit5 min 12 sec
- DevicesDesktop 71% · Mobile 29%
Websites whose visitors overlap most with KBI Biopharma. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| covance.com | 100% | 20.2K | #688,229 | View details | |
fapon.com | fapon.com | 100% | – | ||
| syngeneintl.com | 100% | 94K | #525,515 | View details | |
| avidbio.com | 100% | 12.3K | #1,697,368 | View details | |
| bioreliance.com | 100% | 2.1K | #7,984,772 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 8 similar websites and full traffic analytics for KBI Biopharma
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 8 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Biopharma Outsourcing & Drug Delivery
3 companies that operate in the same segment as KBI Biopharma (Biopharma Outsourcing & Drug Delivery) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Suite solutions are provided for payers and healthcare providers. | 1998 | Princeton, New Jersey, United States | USD 220 M | USD 374.1 M | 5,666 | |
Wearable insulin infusion systems are developed for diabetes patients. | 2000 | Boston, Massachusetts, United States | USD 120.4 M | USD 2.71 B | 3,900 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Kbi Biopharma
Complete news archive for KBI Biopharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about KBI Biopharma
KBI Biopharma was founded in 1996 and raised its 1st funding round 7 years after it was founded.
KBI Biopharma is headquartered in Durham, United States. It is registered at Durham, North Carolina, United States.
KBI Biopharma is a funded company, having raised a total of $17M across 5 funding rounds to date. The company's 1st funding round was a Debt – Venture of $1M, raised on Apr 2003.
KBI Biopharma has 1,243 employees.
Annual revenue of KBI Biopharma is $31.68K as on Dec 31, 2023.
KBI Biopharma was established in 1996 in Durham, United States, within the biopharmaceutical industry. Core operations encompass protein formulation, process and cell line development, alongside cGMP manufacturing services. These activities support biopharmaceutical clients from preclinical stages through to commercial-scale production. The company maintains its primary location in Durham, facilitating services across various global markets.
KBI Biopharma's top competitors include Aldevron and Omnia Biologics.
KBI Biopharma offers Cell Line Development, Process Development, Analytical Development, Formulation Development, and Clinical Manufacturing.
KBI Biopharma has made 1 acquisition, including Alliance Protein Laboratories.
KBI Biopharma has 5 investors. Key investors include NCBiotech, Ballast Point Ventures, INCJ, CMiC, and JSR Life Sciences.
Yes. KBI Biopharma was acquired by JSR Life Sciences in February 2015.